Certis’ orthotopic PDX technique for cancer testing is backed by proven science.

Medicine is science.

This means that everything your doctor does for you—from testing to treatment to follow-up—is based on scientific study and findings. Before you’ll be treated with a therapy, that therapy’s risks, effects and benefits must be known. How well does it work? When does it work? When doesn’t it? Does it work better than another therapy or diagnostic method? In short, everything that happens in medicine must be studied thoroughly and backed by hard scientific data.

Advanced testing proven by dozens of scientific studies.

At Certis Oncology Solutions, our testing methods and protocols were built upon a long legacy of medical science. As scientists do, we had questions, insights and ideas that extended the legacy science, leading us to test new hypotheses, collect new data and adopt methods based on the evidence.

Now fully operational and actively helping people with stage 3 or 4 cancer to have more time and live a higher quality of life, Certis provides testing that has been evaluated and validated by more than 40 different scientific studies. Published in peer-reviewed journals such as JCO Precision Oncology, Cell Cycle, Journal of Cellular Biochemistry, Oncotarget and others, these studies are the basis for Certis’ unique cancer-testing methods…and the proof that they work.

Here’s what the science tells us.

Among other things, the peer-reviewed studies show that surgically implanting tumor tissue orthotopically (“in the correct place”) provides the fastest and most accurate route to discovering which drug has the best chance against your cancer. Specifically, science has shown that…

  • A tumor’s microenvironment is important to the tumor cells’ successful establishment in mice and the clinical relevance/correlation between the mouse tumors and the tumor in the patient. It’s not enough to just implant the tumor cells anywhere in the mice.
  • Orthotopic (“in the correct place”) PDX models metastasize similarly to clinical cancer, enabling testing not just on primary tumors but on metastatic tumors as well. Our metastatic models were found to have the highest relevance for simulating the human condition.
  • Orthotopic PDX models are the most clinically relevant for drug discovery and evaluation.
  • Orthotopic PDX models usually establish—grow to appropriate size for testing—in 4+ months. Establishment for ectopic (“in the wrong place”) PDXs, such as subcutaneous typically takes 6 to 9 months.
  • Orthotopic PDXs lead to faster results than other types of PDX models.
  • We’ve found that our metastatic models are the most relevant models to simulate the human condition.

To read the studies for yourself, visit our Featured Studies page here.

For more information about Certis’ testing, the science behind it, or how to get started, call 866-259-0170 or contact us using our easy online form.